NCT00012181 - Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2001

Primary Completion Date

January 31, 2005

Conditions

Recurrent Childhood Brain Stem GliomaRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood Large Cell LymphomaRecurrent Childhood Liver CancerRecurrent Childhood Lymphoblastic LymphomaRecurrent Childhood Malignant Germ Cell TumorRecurrent Childhood MedulloblastomaRecurrent Childhood RhabdomyosarcomaRecurrent Childhood Small Noncleaved Cell LymphomaRecurrent Childhood Soft Tissue SarcomaRecurrent Childhood Supratentorial Primitive Neuroectodermal TumorRecurrent Childhood Visual Pathway and Hypothalamic GliomaRecurrent Childhood Visual Pathway GliomaRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorRecurrent NeuroblastomaRecurrent OsteosarcomaRecurrent RetinoblastomaRecurrent Wilms Tumor and Other Childhood Kidney TumorsRecurrent/Refractory Childhood Hodgkin LymphomaUnspecified Childhood Solid Tumor, Protocol Specific

Interventions

DRUG

alvocidib

Given IV

OTHER

pharmacological study

Correlative studies

Trial Locations (1)

91006-3776

COG Phase I Consortium, Arcadia

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH